Accessibility Menu

Silexion Therapeutics

(NASDAQ) SLXN

Current Price$2.59
Market Cap$2.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-98%
1 Month-41%

Silexion Therapeutics Financials at a Glance

Market Cap

$2.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.91M

EPS (TTM)

-$94.56

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$2.59

Volume

154

Open

$2.59

Previous Close

$2.74

Daily Range

$2.59 - $2.59

52-Week Range

$2.31 - $223.60

Estimated Earnings Date

Aug 11, 2026

SLXN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silexion Therapeutics

Industry

Biotechnology

Employees

14

CEO

Ilan Hadar, MBA

Headquarters

Jerusalem, 9112001, IL

SLXN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-516.87%

Return on Capital

378.77%

Return on Assets

-280.53%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.06M

Volume

154

Avg. Volume

638.57K

Financials (TTM)

Gross Profit

-$6.00K

Operating Income

$10.53M

EBITDA

-$12.89M

Operating Cash Flow

-$12.01M

Capital Expenditure

-$3.00K

Free Cash Flow

-$12.02M

Cash & ST Invst.

$2.41M

Total Debt

$436.00K

Silexion Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$208.06K

N/A

Employees

14

N/A

Net Income

-$2.73M

-57.5%

EBITDA

-$2.73M

-58.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.41M

-60.8%

Total Debt

$436.00K

-87.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$251.00K

-92.5%

Short Term Debt

$185.00K

+19.4%

Return on Assets

-2.81%

N/A

Return on Invested Capital

19.43%

N/A

Free Cash Flow

-$3.65M

-48.3%

Operating Cash Flow

-$3.65M

-48.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INDPIndaptus Therapeutics, Inc.
$2.42-9.36%
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
ENVBEnveric Biosciences, Inc.
$1.37-5.52%
SCNIScinai Immunotherapeutics Ltd.
$0.26+0.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$71.91-0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.16-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.55+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.27-0.04%

Questions About SLXN

What is the current price of Silexion Therapeutics?

Silexion Therapeutics is trading at $2.59 per share.

What is the 52-week range for Silexion Therapeutics?

Over the past 52 weeks, Silexion Therapeutics has traded between $2.31 and $223.60.

How much debt does Silexion Therapeutics have?

As of the most recent reporting period, Silexion Therapeutics reported total debt of $1.99M.

How much cash does Silexion Therapeutics have on hand?

Silexion Therapeutics reported $2.44M in cash and cash equivalents in its most recent financial results.

What is Silexion Therapeutics’s dividend yield?

Silexion Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.